Europe Tumor Ablation Market Report and Forecast 2024-2032

Europe Tumor Ablation Market Report and Forecast 2024-2032

Europe Tumor Ablation Market Report and Forecast 2024-2032 

Europe Tumor Ablation Market Outlook 

The Europe tumor ablation market size was valued at USD 0.3 billion in 2023, driven by the rising preference for minimally invasive treatment procedures in the region. The market is expected to grow at a CAGR of 12.90% during the forecast period of 2024-2032, with the values likely to rise from USD 0.4 billion in 2024 to USD 0.9 billion by 2032.

Key Takeaways

• In December 2023, Clinical Laserthermia Systems (CLS) participated in IRMPROFT (a research study) with its TRANBERG system, a cutting-edge solution for minimally invasive, image-guided focal laser ablation aimed at treating cancer. The application of tumor ablation with combination therapies is projected to increase the Europe tumor ablation market growth in the forecast period.
• The market is affected by the rising number of FDA approvals for new tumor ablation systems, including Medtronic receiving a 510(k) clearance for OsteoCool™ 2.0, their new tumor ablation system.
• Cancer is the fourth most common cause of death in Europe, causing the tumor ablation market to keep expanding with innovations and technological advancements.

Europe Tumor Ablation Market Analysis

Tumor ablation is a minimally invasive procedure that uses extreme heat or cold to shrink or destroy tumors. It involves inserting a needle-tipped catheter into the tumor with the help of imaging guidance. The technological advancements along with the innovation of new procedures are expected to generate profitable opportunities, thereby, contributing to increased Europe tumor ablation market share.

The rising geriatric population and growing prevalence of cancer cases are amongst some of the most influential factors responsible for driving the growth of the market. After cardiovascular diseases, cancer is the most common cause of death and morbidity in Europe accounting for more than 3.7 million new cases and 1.9 million deaths each year in Europe. The market is also experiencing significant traction due to the rising demand for minimally invasive treatments and increasing awareness about ablation procedures, propelling the heightening of the Europe tumor ablation market demand.

In March 2024, Medtronic plc received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool™ 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma. Integrated with several new features OsteoCool is poised to bring innovation to the market. Portfolio expansions by market players are expected to influence the Europe tumor ablation market size in the coming years.

The market is further influenced by the increasing number of research activities, and efforts of key players towards expanding their global footprint as well as enhance the existing technologies present in the market. In December 2023, Clinical Laserthermia Systems (CLS) announced participation in a new research study, called IRMPROFT, to examine the use of MRI in combination with biopsies to diagnose residual prostate cancer post-focal therapy. The company is participating in this study with their TRANBERG system, a cutting-edge solution for minimally invasive, image-guided focal laser ablation aimed at treating cancer. The application of tumor ablation in combination with other therapies is poised to drive market growth in the forecast period.

Europe Tumor Ablation Market Segmentation  

Market Breakup by Technology

• Kidney Cancer
• Liver Cancer
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Bone Cancer

Market Breakup by Application

• Kidney Cancer
• Liver Cancer
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Bone Cancer

Market Breakup by Treatment

• Surgical Ablation
• Laparoscopic Ablation
• Percutaneous Ablation

Market Breakup by End User

• Hospitals
• Cancer Specialty Clinics
• Others

Market Breakup by Country

• United Kingdom
• Germany
• France
• Italy

Europe Tumor Ablation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows: 

• EDAP TMS
• Mermaid Medical
• BVM Medical Limited
• Cortex Technology
• Olympus Corporation
• BIOTRONIK SE & Co KG
• Boston Scientific Corporation
• Medtronic plc
• AngioDynamics, Inc.
• Merit Medical Systems, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report. 

FAQs

• What was the Europe tumor ablation market value in 2023?  

The market attained a value of about USD 0.3 billion in 2023 driven by the rising geriatric population in the region.

• What is the Europe tumor ablation market forecast outlook for 2024-2032?  

The market is anticipated to grow at a CAGR of 12.92% during the forecast period of 2024-2032, likely to reach a market value of USD 0.9 billion by 2032.  

• What are the major factors aiding the Europe tumor ablation market demand?

Factors contributing to the market demand include the rising geriatric population and the prevalence of cancer in the region.

• What are the major Europe tumor ablation market trends? 

One of the significant trends in the market is the increasing technological advancement in the ablation processes like microwave ablation, and cryoablation among others.

• What is the market segmentation based on technology?

By technology, the market is segmented into radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and other ablation technologies.

• Where does tumor ablation find applications in the market?

It finds wide applications in kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and bone cancer.

• What is the market breakup by treatment?

By treatment, the market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation.

• What are the major end users of tumor ablation?

End users of the market are hospitals, cancer specialty clinics, and others.

• What is the market segmentation by countries? 

The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.

• Who are the key players involved in the European tumor ablation market?

The key players in the market are EDAP TMS, Mermaid Medical, BVM Medical Limited, Cortex Technology, Olympus Corporation, BIOTRONIK SE & Co KG, Boston Scientific Corporation, AngioDynamics, Inc., Merit Medical Systems, Inc., and Medtronic plc.

Meta description

The Europe tumor ablation market size was valued at USD 0.3 billion in 2023 and it is anticipated to grow at a CAGR of 12.92% during the forecast period of 2024-2032. 

*Please Note:* The report will take 7 business days to complete, after order confirmation.